PCOS Is Now PMOS: Understanding the New Terminology and Its Metabolic Implications

PCOS is now PMOS. Learn what polyendocrine metabolic ovarian syndrome means and how insulin resistance influences symptoms and long-term metabolic health. CASI Editorial Team Jun 11, 2026 For nearly nine decades, clinicians have used the term "polycystic ovary syndrome" to describe one of the most common endocrine conditions affecting women of reproductive age. That name is now officially retired. On May 12, 2026, a large consensus paper published in The Lancet formally announced the renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS). The name change was the result of a global consensus process involving 56 leading academic, clinical, and patient organizations and over 22,000 survey responses collected across more than a decade of advocacy. In the final survey, 85.6% of patients and 76.1% of health professionals agreed with the change. This is not merely a semantic update. It is a long-overdue correction that has the potential to reshape how providers diagnose, treat, communicate about, and fund research for this condition. Limitations of the Old Name (PCOS) The term “polycystic ovary syndrome” was first introduced in 1935, born from the...